Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5440_Библиотеки_им_академика_М_И_Перельмана.pdf
13.9 Conclusion 303
(Figure 13.3). This method allows for multiple response optimization, which is crucial in the
pharmaceutical industry, where products have numerous CQAs requiring simultaneous enhance-
ment. Moreover, DoE contributes to the robustness of products or processes, making them less
sensitive to external influences, and ensures protection from outliers through effective identifi-
cation within structured experimental matrices. In essence, DoE emerges as a comprehensive
and powerful approach that not only enhances efficiency and precision but also fortifies the prod-
uct or process against various challenges, reinforcing its reliability in pharmaceutical research and
development [85].
In contrast, OFAT approaches focus on pinpointing local suboptimal regions by altering one fac-
tor at a time. However, this outdated and time-consuming technique lacks the capability to concur-
rently study multiple factor changes or identify causal relationships, including interactions. These
limitations render OFAT unsuitable for QbD applications, where a more holistic and efficient
approach, such as DoE, is essential for gaining a comprehensive understanding of the multifaceted
relationships between various factors influencing the desired outcomes [85].
13.9 Conclusion
In conclusion, the rational design of natural products for drug discovery has seen remarkable pro-
gress with the integration of computational studies. The utilization of computational approaches
offers several advantages, including the ability to expedite the identification of potential drug can-
didates, rationalize molecular interactions, and predict pharmacokinetic properties. By leveraging
computational tools, researchers can efficiently sift through vast chemical space, thereby minimizing
the time and resources required for traditional experimental methods. Moreover, computational
studies facilitate the exploration of complex molecular mechanisms underlying disease pathogen-
esis, enabling the design of more potent and selective therapeutics. The synergy between
Critical
quality
attributes
Quality
by
design
(QbD)
Critical
process
parameters
Quality
target
product
profile
Control
strategy
Design
space
Risk
assessment
Figure 13.3 QbD in rational product
development.
304
computational and experimental techniques enhances the efficiency of drug discovery pipelines,
leading to the development of novel drugs with improved efficacy and safety profiles. The pharma-
ceutical industry initially lagged behind in adopting progressive methodologies, notably focusing
on blockbuster drugs and relying on OFAT studies for formulation development. This delayed
embrace of advanced approaches like QbD and modern engineering-based manufacturing meth-
odologies hindered the sector’s overall evolution compared to other industries. However, within
natural product development, the implementation of QbD has become crucial, with DoE emerging
as a prominent mathematical modeling approach. DoE plays a pivotal role in QbD by establishing
models that correlate CPPs and material attributes (CMAs) with CQAs, defining the design space.
This comprehensive understanding of the product and process facilitates the assurance of quality
in the final product, aligning with the quality target product profile. The review underscores the
significance of QbD principles, tracing their evolution and emphasizing the central role of DoE as
the primary tool for rational pharmaceutical development, particularly in the context of natural
product development.
References
1 Mahapatra, M.K. and Karuppasamy, M. (2022). Fundamental considerations in drug design. In:
Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches,
17–55. Elsevier.
2 Simoben, C.V., Babiaka, S.B., Moumbock, A.F.A. et al. (2023). Challenges in natural product-based
drug discovery assisted with in silico-based methods. RSC Advances [Internet] 13 (45): 31578.
3 Kitchen, D.B. (2017). Computer-aided drug discovery research at a global contract research
organization. Journal of Computer-Aided Molecular Design [Internet] 31 (3): 309–318. https://doi.
org/10.1007/s10822-016-9991-3.
4 Morelli, X. and Rigby, A.C. (2007). Acceleration of the drug discovery process: a combinatorial
approach using NMR spectroscopy and virtual screening. Current Computer-Aided Drug Design
3 (1): 33–49.
5 Ejalonibu, M.A., Ogundare, S.A., Elrashedy, A.A. et al. (2021). Drug discovery for Mycobacterium
tuberculosis using structure-based computer-aided drug design approach. International Journal of
Molecular Sciences [Internet] 22 (24).
6 Arora, D.D. and Kumar, D.M. (2002). Rational use of ayurvedic literaature for drug development.
Ancient Science of Life [Internet] 21 (3): 182.
7 Tuteja, R. and Tuteja, N. (2004). Serial analysis of gene expression: applications in human studies.
Journal of Biotechnology and Biomedicine [Internet] 2004 (2): 113.
8 Bai, Y., Zhang, L., and Lei, X. (2021). Human endogenous natural products. Progress in the
Chemistry of Organic Natural Products [Internet] 114: 313–337.
9 Tan, G., Gyllenhaal, C., and Soejarto, D. (2006). Biodiversity as a source of anticancer drugs.
Current Drug Targets [Internet] 7 (3): 265–277.
10 Harvey, A.L., Clark, R.L., Mackay, S.P., and Johnston, B.F. (2010). Current strategies for drug
discovery through natural products. Expert Opinion on Drug Discovery [Internet] 5 (6): 559–568.
11 Grabley, S. and Thiericke, R. (1999). Bioactive agents from natural sources: trends in discovery and
application. Advances in Biochemical Engineering/Biotechnology [Internet] 64: 101–154.
12 Amirkia, V. and Heinrich, M. (2015). Natural products and drug discovery: a survey of stakeholders
in industry and academia. Frontiers in Pharmacology [Internet] 6 (Oct).
eferences 305
13 Crane, E.A. and Gademann, K. (2016). Capturing biological activity in natural product fragments
by chemical synthesis. Angewandte Chemie International Edition [Internet] 55 (12): 3882–3902.
14 Sharma, S.B. and Gupta, R. (2015). Drug development from natural resource: a systematic
approach. Mini-Reviews in Medicinal Chemistry [Internet] 15 (1): 52–57.
15 Kim, H.K., Choi, Y.H., and Verpoorte, R. (2023). Natural products drug discovery: on silica or in-
silico? Handbook of Experimental Pharmacology [Internet] 277: 117–141.
16 Barba-Ostria, C., Carrera-Pacheco, S.E., Gonzalez-Pastor, R. et al. (2022). Evaluation of biological
activity of natural compounds: current trends and methods. Molecules [Internet] 27 (14).
17 Glassman, P.M. and Muzykantov, V.R. (2019). Pharmacokinetic and pharmacodynamic
properties of drug delivery systems. Journal of Pharmacology and Experimental Therapeutics
[Internet] 370 (3): 570.
18 Thomford, N.E., Senthebane, D.A., Rowe, A. et al. (2018). Natural products for drug discovery in
the 21st century: innovations for novel drug discovery. International Journal of Molecular Sciences
[Internet] 19 (6).
19 Atanasov, A.G., Zotchev, S.B., Dirsch, V.M. et al. (2021). Natural products in drug discovery:
advances and opportunities. Nature Reviews Drug Discovery [Internet] 20 (3): 200–216.
20 Hong, J. (2011). Role of natural product diversity in chemical biology. Current Opinion in Chemical
Biology [Internet] 15 (3): 350–354.
21 Ertl, P. and Schuffenhauer, A. (2009). Estimation of synthetic accessibility score of drug-like
molecules based on molecular complexity and fragment contributions. Journal of Cheminformatics
[Internet] 1 (1).
22 David, F., Davis, A.M., Gossing, M. et al. (2021). A perspective on synthetic biology in drug
discovery and development-current impact and future opportunities. SLAS Discovery: Advancing
Life Sciences R&D [Internet] 26 (5): 581–603.
23 Niesenbaum, R.A. (2019). The integration of conservation, biodiversity, and sustainability.
Sustainable [Internet] 11 (17): 4676.
24 Dzobo, K. (2022). The role of natural products as sources of therapeutic agents for innovative drug
discovery. Comprehensive Pharmacology [Internet] 2: 408.
25 Linhares, Y., Kaganski, A., Agyare, C. et al. (2023). Biodiversity: the overlooked source of human
health. Trends in Molecular Medicine [Internet] 29 (3): 173–187.
26 Dias, D.A., Urban, S., and Roessner, U. (2012). A historical overview of natural products in drug
discovery. Metabolites [Internet] 2 (2): 303.
27 Von Nussbaum, F., Brands, M., Hinzen, B. et al. (2006). Antibacterial natural products in
medicinal chemistry – exodus or revival? Angewandte Chemie International Edition [Internet]
45 (31): 5072–5129.
28 Neergheen-Bhujun, V., Awan, A.T., Baran, Y. et al. (2017). Biodiversity, drug discovery, and the
future of global health: introducing the biodiversity to biomedicine consortium, a call to action.
Journal of Global Health [Internet] 7 (2).
29 Alves, R.R.N. and IML, R. (2007). Biodiversity, traditional medicine and public health: where do
they meet? Journal of Ethnobiology and Ethnomedicine [Internet] 3.
30 Cragg, G.M. and Newman, D.J. (2013). Natural products: a continuing source of novel drug leads.
Biochimica et Biophysica Acta [Internet] 1830 (6): 3670–3695.
31 Bernardini, S., Tiezzi, A., Laghezza Masci, V., and Ovidi, E. (2018). Natural products for human
health: an historical overview of the drug discovery approaches. Natural Product Research
[Internet] 32 (16): 1926–1950.
32 Lautié, E., Russo, O., Ducrot, P., and Boutin, J.A. (2020). Unraveling plant natural chemical
diversity for drug discovery purposes. Frontiers in Pharmacology [Internet] 11.
306
33 Urban, S. and Dias, D.A. (2013). NMR spectroscopy: structure elucidation of cycloelatanene A: a
natural product case study. Methods in Molecular Biology [Internet] 1055: 99–116.
34 Bouslimani, A., Sanchez, L.M., Garg, N., and Dorrestein, P.C. (2014). Mass spectrometry of natural
products: current, emerging and future technologies. Natural Product Reports [Internet] 31 (6):
718–729.
35 Přichystal, J., Schug, K.A., Lemr, K. et al. (2016). Structural analysis of natural products. Analytical
Chemistry [Internet] 88 (21): 10338–10346.
36 Sliwoski, G., Kothiwale, S., Meiler, J., and Lowe, E.W. (2014). Computational methods in drug
discovery. Pharmacological Reviews [Internet] 66 (1): 334.
37 Morris, G.M. and Lim-Wilby, M. (2008). Molecular docking. Methods in Molecular Biology
[Internet] 443: 365–382.
38 Wang, Y., Hu, J.S., Lin, H.Q. et al. (2016). Herbalog: a tool for target-based identification of herbal
drug efficacy through molecular docking. Phytomedicine [Internet] 23 (12): 1469–1474.
39 Medina-Franco, J.L. and Saldívar-González, F.I. (2020). Cheminformatics to characterize
pharmacologically active natural products. Biomolecules [Internet] 10 (11): 1–14.
40 Gogoi, N., Chowdhury, P., Goswami, A.K. et al. (2022). Integrated computational approach towards
repurposing of antimalarial drug against SARS-CoV-2 main protease. Structural Chemistry
[Internet] 0123456789. https://doi.org/10.1007/s11224-022-01916-0.
41 Puthanveedu, V. and Muraleedharan, K. (2022). Phytochemicals as potential inhibitors for
COVID-19 revealed by molecular docking, molecular dynamic simulation and DFT studies.
Structural Chemistry [Internet] 33 (5): 1423–1443.
42 Allen, S.E., Dokholyan, N.V., and Bowers, A.A. (2016). Dynamic docking of conformationally
constrained macrocycles: methods and applications. ACS Chemical Biology [Internet] 11 (1): 10–24.
43 Vijayakumari, B., Sasikala, V., Radha, S.R., and Rameshwar, H.Y. (2016). In silico analysis of
aqueous root extract of Rotula aquatica Lour for docking analysis of the compound 3-O-acetyl-11-
keto-β-boswellic acid contents. Springerplus [Internet] 5 (1).
44 Rollinger, J.M., Stuppner, H., and Langer, T. (2008). Virtual screening for the discovery of bioactive
natural products. Progress in Drug Research [Internet] 65: 212–249.
45 Kirchweger, B. and Rollinger, J.M. (2019). A strength-weaknesses-opportunities-threats (SWOT)
analysis of cheminformatics in natural product research. Progress in the Chemistry of Organic
Natural Products [Internet] 110: 239–271.
46 Olgaç, A., Orhan, I.E., and Banoglu, E. (2017). The potential role of in silico approaches to identify
novel bioactive molecules from natural resources. Future Medicinal Chemistry [Internet] 9 (14):
1663–1684.
47 Chen, Y., De Bruyn Kops, C., and Kirchmair, J. (2017). Data resources for the computer-guided
discovery of bioactive natural products. Journal of Chemical Information and Modeling [Internet]
57 (9): 2099–2111. https://doi.org/10.1021/acs.jcim.7b00341.
48 Santana, K., do Nascimento, L.D., Lima e Lima, A. et al. (2021). Applications of virtual screening
in bioprospecting: facts, shifts, and perspectives to explore the chemo-structural diversity of
natural products. Frontiers in Chemistry [Internet] 9.
49 Choi, J., He, N., Kim, N., and Yoon, S. (2012). Enrichment of virtual hits by progressive shape
matching and docking. The Journal of Molecular Graphics and Modelling [Internet] 32: 82–88.
50 Speck-Planche, A. and Cordeiro, M.N.D.S. (2015). Multitasking models for quantitative structure
biological effect relationships: current status and future perspectives to speed up drug discovery.
Expert Opinion on Drug Discovery [Internet] 10 (3): 245–256.
51 Kar, S. and Roy, K. (2012). QSAR of phytochemicals for the design of better drugs. Expert Opinion
on Drug Discovery [Internet] 7 (10): 877–902.
eferences 307
52 Kausar, S. and Falcao, A.O. (2018). An automated framework for QSAR model building. Journal of
Cheminformatics [Internet] 10 (1).
53 Nguyen, G.T.H., Bennett, J.L., Liu, S. et al. (2021). Multiplexed screening of thousands of natural
products for protein–ligand binding in native mass spectrometry. Journal of the American Chemical
Society [Internet] 143 (50): 21379–21387.
54 Eldridge, G.R., Vervoort, H.C., Lee, C.M. et al. (2002). High-throughput method for the production
and analysis of large natural product libraries for drug discovery. Analytical Chemistry [Internet]
74 (16): 3963–3971.
55 Falcón-Cano, G., Cabrera-Pérez, M.Á., and Molina, C. (2020). ADME prediction with KNIME: in
silico aqueous solubility consensus model based on supervised recursive random forest approaches.
ADMET DMPK [Internet] 8 (3): 251.
56 Deng, C., Liang, L., Xing, G. et al. (2023). Multi-channel GCN ensembled machine learning model
for molecular aqueous solubility prediction on a clean dataset. Molecular Diversity [Internet] 27 (3):
1023–1035.
57 Ntie-Kang, F. (2013). An in silico evaluation of the ADMET profile of the StreptomeDB database.
Springerplus [Internet] 2 (1): 1–11.
58 Chen, X.Q., Cho, S.J., Li, Y., and Venkatesh, S. (2002). Prediction of aqueous solubility of organic
compounds using a quantitative structure–property relationship. Journal of Pharmaceutical
Sciences [Internet] 91 (8): 1838–1852.
59 Alqahtani, S. (2017). In silico ADME-Tox modeling: progress and prospects. Expert Opinion on
Drug Metabolism & Toxicology [Internet] 13 (11): 1147–1158.
60 Paul Gleeson, M., Hersey, A., and Hannongbua, S. (2011). In silico ADME models: a general
assessment of their utility in drug discovery applications. Current Topics in Medicinal Chemistry
[Internet] 11 (4): 358–381.
61 Abshear, T., Banik, G.M., D’Souza, M.L. et al. (2006). A model validation and consensus building
environment. SAR and QSAR in Environmental Research [Internet] 17 (3): 311–321.
62 Liang, L., Liu, Y., Kang, B. et al. (2022). Large-scale comparison of machine learning algorithms for
target prediction of natural products. Briefings in Bioinformatics [Internet] 23 (5).
63 Webel, H.E., Kimber, T.B., Radetzki, S. et al. (2020). Revealing cytotoxic substructures in molecules
using deep learning. Journal of Computer-Aided Molecular Design [Internet] 34 (7): 731–746.
64 Kamerlin, N., Delcey, M.G., Manzetti, S., and Van Der Spoel, D. (2020). Toward a computational
ecotoxicity assay. Journal of Chemical Information and Modeling [Internet] 60 (8): 3792–3803.
65 Hu, Z., Wahl, J., Hamburger, M., and Vedani, A. (2016). Molecular mechanisms of endocrine and
metabolic disruption: an in silico study on antitrypanosomal natural products and some
derivatives. Toxicology Letters [Internet] 252: 29–41.
66 Behera, R., Thomas, S.M., and Mensa-Wilmot, K. (2014). New chemical scaffolds for human
african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Antimicrobial Agents and Chemotherapy [Internet] 58 (4): 2202.
67 Zhang, H.W., Lv, C., Zhang, L.J. et al. (2021). Application of omics- and multi-omics-based
techniques for natural product target discovery. Biomedicine & Pharmacotherapy [Internet] 141.
68 Walker, A.S. and Clardy, J. (2021). A machine learning bioinformatics method to predict biological
activity from biosynthetic gene clusters. Journal of Chemical Information and Modeling [Internet]
61 (6): 2560–2571.
69 Zheng, S., Zeng, T., Li, C. et al. (2022). Deep learning driven biosynthetic pathways navigation for
natural products with BioNavi-NP. Nature Communications [Internet] 13 (1).
70 Gu, J., Gui, Y., Chen, L. et al. (2013). Use of natural products as chemical library for drug discovery
and network pharmacology. PLoS One [Internet] 8 (4).
308
71 Blin, K., Kim, H.U., Medema, M.H., and Weber, T. (2019). Recent development of antiSMASH and
other computational approaches to mine secondary metabolite biosynthetic gene clusters. Briefings
in Bioinformatics [Internet] 20 (4): 1103–1113.
72 Decherchi, S. and Cavalli, A. (2020). Thermodynamics and kinetics of drug–target binding by
molecular simulation. Chemical Reviews [Internet] 120 (23): 12788–12833.
73 Atanasov, A.G., Waltenberger, B., Pferschy-Wenzig, E.M. et al. (2015). Discovery and resupply of
pharmacologically active plant-derived natural products: a review. Biotechnology Advances 33 (8):
1582–1614.
74 Yadav, H., Mahalvar, A., Pradhan, M. et al. (2023). Exploring the potential of phytochemicals and
nanomaterial: a boon to antimicrobial treatment. Medicine in Drug Discovery 17: 100151.
75 Aqil, F., Munagala, R., Jeyabalan, J., and Vadhanam, M.V. (2013). Bioavailability of phytochemicals
and its enhancement by drug delivery systems. Cancer Letters 334 (1): 133–141.
76 Singh, M., Devi, S., Rana, V.S. et al. (2019). Delivery of phytochemicals by liposome cargos: recent
progress, challenges and opportunities. Journal of Microencapsulation 36 (3): 215–235.
77 Nasim, N., Sandeep, I.S., and Mohanty, S. (2022). Plant-derived natural products for drug
discovery: current approaches and prospects. The Nucleus 65 (3): 399–411.
78 Testa, B., Crivori, P., Reist, M., and Carrupt, P.A. (2000). The influence of lipophilicity on the
pharmacokinetic behavior of drugs: concepts and examples. Perspectives in Drug Discovery and
Design 19 (1): 179–211.
79 Upadhyay, R.K. (2014). Drug delivery systems, CNS protection, and the blood brain barrier. BioMed
Research International 2014.
80 Rathaur, P. and SR KJ. (2020). Metabolism and pharmacokinetics of phytochemicals in the human
body. Current Drug Metabolism 20 (14): 1085–1102.
81 Zhang, Z. and Tang, W. (2018). Drug metabolism in drug discovery and development. Acta
Pharmaceutica Sinica B 8 (5): 721–732.
82 Mehta, P., Shah, R., Lohidasan, S., and Mahadik, K.R. (2015). Pharmacokinetic profile of
phytoconstituent(s) isolated from medicinal plants– a comprehensive review. Journal of Traditional
and Complementary Medicine 5 (4): 207–227.
83 Chavda, V.P., Nalla, L.V., Balar, P. et al. (2023). Advanced phytochemical-based nanocarrier
systems for the treatment of breast cancer. Cancers 15 (4): 1023.
84 Markovic, M., Ben-Shabat, S., and Dahan, A. (2020). Prodrugs for improved drug delivery: lessons
learned from recently developed and marketed products. Pharm 12 (11): 1031.
85 Politis, S.N., Colombo, P., Colombo, G., and Rekkas, D.M. (2017). Design of experiments (DoE) in
pharmaceutical development. Drug Development and Industrial Pharmacy 43 (6): 889–901.
86 Montgomery, D.C. Design and Analysis of Experiments, 8ee. Wiley.
87 Yu, L.X., Amidon, G., Khan, M.A. et al. (2014). Understanding pharmaceutical quality by design.
The AAPS Journal 16 (4): 771–783.
88 Aminpour, M., Montemagno, C., and Tuszynski, J.A. (2019). An overview of molecular modeling
for drug discovery with specific illustrative examples of applications. Molecules 24 (9): 1693.
89 Adelusi, T.I., Oyedele, A.Q.K., Boyenle, I.D. et al. (2022). Molecular modeling in drug discovery.
Informatics in Medicine Unlocked 29: 100880.
90 Agamah, F.E., Mazandu, G.K., Hassan, R. et al. (2020). Computational/in silico methods in drug
target and lead prediction. Briefings in Bioinformatics 21 (5): 1663–1675.
91 Han, R., Yoon, H., Kim, G. et al. (2023). Revolutionizing medicinal chemistry: the application of
artificial intelligence (AI) in early drug discovery. Pharmaceuticals 16 (9): 1259.
eferences 309
92 Loisios-Konstantinidis, I., Paraiso, R.L.M., Fotaki, N. et al. (2019). Application of the relationship
between pharmacokinetics and pharmacodynamics in drug development and therapeutic
equivalence: a PEARRL review. The Journal of Pharmacy and Pharmacology 71 (4): 699–723.
93 Yang, S. and Kar, S. (2023). Application of artificial intelligence and machine learning in early
detection of adverse drug reactions (ADRs) and drug-induced toxicity. Artificial Intelligence
Chemistry 1 (2): 100011.
94 Pharmaceutical Development (2009). ICH of technical requirements for registration of
pharmaceuticals for human use, pharmaceutical development Q8(R2). International Conference on
Harmonisation https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf.
95 Box, G.E.P. and Wilson, K.B. (1951). On the experimental attainment of optimum conditions.
Journal of the Royal Statistical Society Series B-Methodological [Internet] 13: 1–38.
96 Martins Fukuda, I., Francini, C., Pinto, F. et al. (2018). Design of experiments (DoE) applied to
pharmaceutical and analytical quality by design (QbD). Journal of Pharmaceutical Sciences 54.
311
14.1 Introduction
Enzymes are appealing targets for therapeutic intervention, given that they are crucial in numerous
processes of metabolism. Designing enzyme inhibitors has become a crucial approach in the devel-
opment of pharmaceuticals, giving potential cures for a variety of ailments. By suppressing speci-
fied enzymes, one may alter their activity, disrupt biochemical processes, and subsequently resume
normal physiological processes. However, generating reliable enzyme inhibitors is a challenging,
varied process that requires an array of strategies and confronts an assortment of hurdles [1]. This
chapter attempts to serve as a foundation for the area of enzyme inhibitors, focusing on the meth-
ods adopted and challenges encountered in their development [2]. While highlighting various
inhibitor types and their modes of action, the core concepts of enzyme inhibition were also high-
lighted. Numerous drug design approaches, including computer-aided strategies, ligand-based
approaches, and structure-based discovery of drugs were also explored [3].
As many enzymes have similar biological and structural attributes, acquiring selectivity and
sensitivity in enzyme inhibitor design is one of the primary difficulties [4]. To generate inhibitors
that specifically target the desired enzyme while minimizing off-target effects, it is crucial to com-
prehend the site of activity, docking interactions, and substrate preference of the enzyme [5]. In
addition, difficulties with pharmaceutical kinetics, biological availability, and possible toxic effects
tend to be resolved throughout the fabrication of enzyme inhibitors [6]. The implementation of
prodrugs, prodrug approaches, and formulating strategies are some of the methods being studied
to boost the drug-like attributes and escalate the effectiveness of enzyme inhibitors [7]. This chap-
ter will also provide insight into the constantly evolving field of enzyme inhibitor design, taking
benefit of modern advances like fragment-based discovery of drugs, allosteric suppression, and the
use of modern tools like machine learning and artificial intelligence [8].
Generating new pharmaceuticals that leverage a comprehension of the critical function of
enzymes in ailments and the use of approaches to regulate their activities for medicinal purposes
is a tedious and costly inventive process known as drug discovery and development. This chemo-
therapeutic approach requires the use of the biochemical variances between recipient and patho-
gen cells. These inhibitors modulate the recuperation process by limiting particular metabolic
activity. As a result, pharmacology and the pharmaceutical industry are now adopting a
14
Design of Enzyme Inhibitors in Drug Discovery
Koyel Kar
Department of Pharmaceutical Chemistry, BCDA College of Pharmacy & Technology, Kolkata, West Bengal, India
312
fundamental approach to grasping the role of enzyme inhibitors in drug discovery. An active area
of biochemical and pharmacological research is centered around the detection of intriguing robust
enzyme inhibitors and the ensuing modification of these compounds. Enzyme inhibitors make up
an important percentage of the orally attainable medicinal products already in use, making them
ideal targets for pharmaceutical discovery [9].
The effectiveness of the inhibitor and its suitability for the target enzyme dictate how effective
an enzyme inhibitor is as a drug. These traits, in turn, are impacted by the extent and form of inter-
actions that happen involving the inhibitor and the enzyme. To design new medications, it is ben-
eficial to screen low molecular weight molecules against both emerging and traditional protein
targets. The three-dimensional arrangements of these enzymes, whether in free form or bound to
inhibitors that were formerly known to exist, digging into vast chemical databases, or the incorpo-
ration of an array of computer-assisted methodologies are usually what make such a drug design
process for a single enzyme target more efficient [10].
14.2 Importance of Enzyme Inhibition as a Strategy
for Modulating Enzyme Activity
By emphasizing certain enzymes implicated in the development of diseases, enzyme inhibitors are
essential in the medication emergence process. A successful approach for governing enzymatic
activity and obstructing disease-related processes is enzyme inhibition. The enzyme’s active site is
in confrontation with inhibitors and the substrate. Inhibitors disrupt an enzyme’s function or
structure by adhering to a different location on the enzyme. Inhibitors adhere to the enzyme–
substrate complex and suppress the generation of compounds [11]. It leverages the intended
enzyme’s three-dimensional framework to generate inhibitors that can occupy the active site. It
uses data about the known ligands or substrates of the enzyme to build inhibitors with comparable
characteristics. In the process of uncovering new drugs, enzyme inhibitors are crucial. The key
cause of disorders, as discovered by molecular analysis, is the malfunction, overexpression, or
excessive stimulation of the implicated enzymes. Effective enzyme inhibitors can be used to allevi-
ate this escalated activation or overexpression of enzymes. Several enzyme inhibitors are already
accessible at medical facilities [12].
14.3 Classification of Enzyme Inhibitors
14.3.1 Reversible Inhibitors
An enzyme is rendered latent by a reversible inhibitor through noncovalent interactions. A
reversible inhibitor may differentiate from the enzyme as opposed to an irreversible inhibitor.
Reversible inhibitors exist in various other forms. Any substance that structurally replicates an
identifiable substrate and hence confronts it for binding to the center of activity of an enzyme is
deemed to be a competitive inhibitor. The enzyme does not interact with the inhibitor, but it hin-
ders the substrate from getting adjacent to the active site [13]. The relative quantities of a sub-
strate and a competitive inhibitor dictate how much they impair an enzyme’s ability to function.
The inhibitor will initially block the majority of the active sites if it is present in relatively high
concentrations. However, some substrate molecules will eventually adhere to the active site
owing to the reversible aspect of the association and transform into a product. An elevated